Abstract
For more than 2 years, COVID-19 has been holding the world at awe with new waves of infections, novel mutants, and still limited (albeit improved) means to combat SARS-CoV-2-induced respiratory failure, the most common and fatal presentation of severe COVID-19. In the present perspective, we draw from the successes and-mostly-failures in previous acute respiratory distress syndrome (ARDS) work and the experiences from COVID-19 to define conceptual barriers that have so far hindered therapeutic breakthroughs in this deadly disease, and to open up new avenues of thinking and thus, ultimately of therapy.
| Original language | English |
|---|---|
| Pages (from-to) | L431-L437 |
| Journal | American journal of physiology. Lung cellular and molecular physiology |
| Volume | 323 |
| Issue number | 4 |
| Early online date | 23 Aug 2022 |
| DOIs | |
| Publication status | Published - 1 Oct 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- ARDS
- COVID-19
- endothelial
- treatment
- ventilator-induced lung injury
Fingerprint
Dive into the research topics of 'ARDS in the time of corona: context and perspective'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver